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Abstract Pancreatic ductal adenocarcinoma (PDAC) has one
of the worst survival rates of all cancers. ANO1 (TMEM16A)
is a recently identified Ca2+-activated Cl− channel (CaCC) that
is upregulated in several tumors. Although ANO1 was subject
to extensive studies in the recent years, its pathophysiological
function has only been poorly understood. The aim of the
present study is to establish the significance of ANO1 in
PDAC behavior and demarcate its roles in PDAC from those
of the volume-regulated anion channel (VRAC). We per-
formed qPCR and Western blot measurements on different
PDAC cell lines (Panc-1, Mia PaCa 2, Capan-1, AsPC-1,
BxPC-3) and compared the results to those obtained in a
human pancreatic ductal epithelium (HPDE) cell line. All
cancer cell lines showed an upregulation of ANO1 on
mRNA and protein levels. Whole-cell patch-clamp recordings
identified large Ca2+ and voltage-dependent Cl− currents in
PDAC cells. Using siRNA knockdown of ANO1 and three
ANO1 inhibitors (T16Ainh-A01, CaCCinh-A01, and NS3728),
we found that ANO1 is the main constituent of CaCC current
in PDAC cells. We further characterized these three inhibitors
and found that they had unspecific effects on the free intracel-
lular calcium concentration. Functional studies on PDAC
behavior showed that surprisingly inhibition of ANO1 did
not influence cellular proliferation. On the other hand, we
found ANO1 channel to be pivotal in PDAC cell migration
as assessed in wound healing experiments.
Keywords Cl− channel . TMEM16A . VRAC . LRRC8 .
Cancer . Proliferation .Migration . Pancreas
Introduction
Pancreatic ductal adenocarcinoma (PDAC) has one of the
worst prognoses of all cancers, with a 5-year survival rate of
less than 5 %. Incidence of PDAC correlates with increasing
age and therefore is an increasing problem as world popula-
tion is aging [16]. Dysfunction of ion channels is an emerging
field in cancer research and differential expression of multiple
classes of ion channels has been reported for different cancer
tissues [20–22, 28, 29, 31, 35, 43]. Plasma membrane ion
channels are involved in apoptosis [19], differentiation, and
proliferation [17, 28], and are further associated with cell
migration [15, 38] and cell volume regulation [14]. The latter
is a crucial factor in regulation of cell proliferation (see [14])
and apoptosis [33], key processes that are usually deregulated
in cancer [11].
In epithelia, including pancreatic ducts, Ca2+-activated Cl−
channel (CaCC) is important for secretory processes [27]. One
of the favored molecular candidates for CaCC is the recently
identified ANO1 (also known as TMEM16A, TAOS2,
ORAOV2, and DOG1) [4, 9, 37, 48]. ANO1 is located on
the amplicon 11q13 that is frequently amplified in human
cancers with poor prognosis [1, 7, 26, 46]. ANO1 was shown
to be upregulated in several cancer tissues including head and
neck squamous cell carcinoma (HNSCC) and prostate-,
breast-, and pancreatic cancer [1, 2, 22, 23, 45]. However,
the physiological function of ANO1 has been found to vary
among different cancer tissues. A pro-proliferative role of
ANO1 was reported for breast- and prostate cancer [3, 22,
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23], but this was not confirmed in HNSCC cells [1, 35].
Contradictory results are reported in the pancreatic cancer cell
line CFPAC-1. Thus, Ruiz et al. [35] found a slight anti-
proliferative effect of ANO1 using a knockdown and an
overexpression strategy, whereas Mazzone et al. [23] showed
a decrease in proliferation after application of the recently
developed ANO1-specific inhibitor T16Ainh-A01 (10 μM)
[5, 23, 35]. ANO1 was further associated with cellular attach-
ment, spreading, detachment, and invasion [1, 15]. All these
studies used cell lines highly overexpressing ANO1 or with
knockdown of ANO1 to assess its pathophysiological func-
tion, but suffered from the lack of a normal pancreatic epithe-
lial cell control system for comparison.
A volume-regulated anion channel (VRAC), which is in-
volved in restoring cell volume upon external osmotic perturba-
tion, has been studied in several types of mammalian cells [14].
Synthesis of high-affinityCl− channel inhibitors, such asNS3728
[12], has facilitated insight in VRAC’s physiological role in cell
cycle progression. A four-transmembrane protein, the Leucine-
rich repeat-containing protein 8 (LRRC8),was recently identified
as a main constituent of the VRAC current [32, 44].
The aim of the present study was to elucidate the role of
ANO1 in PDAC behavior, compare it to a normal model cell
line, and demarcate the roles of ANO1 from those of VRAC.
Materials and methods
Cell culture and transfection
All cell lines were grown at 37 °C and 5% CO2. Immortalized
human pancreatic ductal epithelium (HPDE) (H6c7 cell line,
kind gift of Dr. M-S. Tsao from University Health Network in
Toronto [8, 27]) cells were grown in keratinocyte serum-free
medium supplemented by epidermal growth factor and bovine
pituitary extract (Life Technologies, Inc., USA). Cells were
passaged by gently trypsinization, subsequent neutralization
with trypsin inhibitor (soybean, Life Technologies, Inc.,
USA), centrifugation (700 rpm/3 min), and resuspension.
All cancer cells (obtained from ATCC, Germany) were pas-
saged every 4–6 days by gently trypsinization. Panc-1 and
Mia PaCa-2 were grown in Dulbecco’s Modified Eagle
Medium with stable glutamine (DMEM/Biochrom,
Germany), BxPC-3 and AsPC-1 in Roswell Park Memorial
Ins t i tu te medium with s table glu tamine (RPMI
1640/Biochrom, Germany), and Capan-1 in Iscove’s
Modified Dulbecco’s Medium (IMDM-1640/Biochrom,
Germany), all were supplemented with 10 % v/v (20 % for
Capan-1) Fetal Bovine Serum “Gold” (PAA Laboratories
GmbH, Germany). Mia PaCa-2 growth medium was further
supplemented with 2.5 % v/v horse serum (Biochrom,
Germany). All cultures were further supplemented with 1 %
v/v penicillin and streptomycin.
DharmaFECT 1 Transfection Reagent (Thermo Scientific,
Germany) was used for transfection of siRNA targeting
ANO1 (50 nM final concentration) or scrambled (5 nM final
concentration). Cells were transfected according to the manu-
facturer’s protocol. Predesigned siRNA oligo was obtained
from Sigma-Aldrich (5 ′-CCUUCAACGUCAGUGA
CUU[dT] [dT] -3 ′ , 5 ′ -AAGUCACUGACGUUGA
AGG[dT][dT]-3′) or negative control (Silencer® Negative
Control No. 1 siRNA; Ambion, Denmark). ANO1 overex-
pressing HEK293 cells were generated by adding 0.5 μg/ml
mANO1-GFP vector to DMEM containing 1 % v/v penicillin
and streptomycin. The mixture was vortexed and incubated
for 5 min, and 20 μg/ml polyethylenimine (PEI) was added.
The mixture was vortexed again and added drop-wise to 60 %
confluent HEK293 cells in DMEM medium containing 5 %
v/v FBS and 1 % v/v penicillin and streptomycin after 10 min
incubation at room temperature. Media was changed after 4 h
incubation at 37 °C and 5 % CO2.
Isolation of RNA, cDNA, and qPCR
Total RNAwas extracted from cell cultures using Nucleo Spin
II (MACHEREY-NAGEL, Germany). First strand comple-
mentary DNAs were synthesized using Superscript II
(Invitrogen, Denmark) and Oligo-dTs following the manufac-
turer’s guidelines. PCR reaction mixtures were prepared using
the FastStart Universal SYBR Green Master (Rox) mix
(Roche, Denmark). Quantitative PCR experiments were car-
ried out in triplicates. Primers used were as follows: ANO1-
sense 5′-GCGTCCACATCATCAACATC-3′ and ANO1-
antisense 5′-ATCCTCGTGGTAGTCCATCG-3′ [41]. ANO1
expression levels were normalized to the reference gene β-
actin. The fold-change in gene expression was determined by
the ΔΔC(t) method [36]. Data were expressed as expression
relative to that in the control cell line HPDE.
Electrophysiology
Cells were grown on poly-L-lysine coated coverslips. For
knockdown experiments, cells were transfected with siRNA
targeting ANO1 or scrambled siRNA shortly after complete
attachment of the cells (approx. 3 h after plating). Currents
were measured 36–48 h after transfection. Whole-cell patch-
clamp recordings were performed using the Axopatch 200B
amplifier interfaced to a Digidata 1440A controlled by
pClamp10 software (Molecular Devices, USA). Analogue
signals were acquired at 2.5 kHz and filtered at 1 kHz. Patch
electrodes were pulled from borosilicate glass and had an
input resistance of 2–6 MΩ, when filled with pipette solution
(below). An agar bridge made of 3 % agar and 97 % of the
bath solution containing NMDG-Cl (below) was used as
reference electrode. Current activations were recorded from
an output holding potential, Vout=0 mV with ramp protocols
Pflugers Arch - Eur J Physiol
spanning from −100 to 100 mVover 1 s and run continuously
with 15-s intervals. Step protocols between −100 to 120 mV
were generated from Vout=0 mV with step increments of
20 mVand lengths of 2 s. Liquid junction potentials (Vlj) were
estimated as described in [10] with membrane potentials cal-
culated as, Vm=Vout−Vlj. Series resistance was compensated
by 60–70 %. All recordings were performed at room temper-
ature (18–23 °C). Instantaneous currents were measured 1 ms
after each voltage step. The data was fitted using the
Goldman–Hodgkin–Katz (GHK) current equation.
ICl− ¼ Pz
2F2V
RT
Co−Cie
zFV
RT
1−ezFVRT
ð1Þ
Here, ICl− is the current carried across the membrane by
Cl− ions, P is the permeability of the membrane for Cl−, z is
the valence (−1), F is the Faraday constant, V is the membrane
voltage, R is the universal gas constant, T is the absolute
temperature, Co and Ci are the extra- and intracellular concen-
tration of Cl−, respectively. Steady-state permeability was
calculated by solving Eq. 1 for P. The Boltzmann distribution
(Eq. 2) was fitted to the permeabilities obtained above.
PCl: ¼ Pmax þ Pmin−Pmaxð Þ
1þ e
V−V1=2
dV
ð2Þ
V1/2 is the voltage for half-maximal activation of the chan-
nels. The curves were normalized to Pmin=0 and Pmax=1.
Solutions
One micromolar free Ca2+ pipette solution include the follow-
ing (in mM): 100 CsAsp, 40 CsCl, 4.34 CaCl2, 4 Na2ATP, 1
MgCl2, 5 EGTA, 10 HEPES, pH 7.2, osmolality 295 mosmol/
kg or 0 μM free Ca2+ solution containing no CaCl2 and 10 mM
EGTA. Standard bath solution include the following (in mM):
150 NaCl, 1.5 CaCl2, 1MgCl2, 10 glucose, 10 HEPES, pH 7.4,
osmolality 315 mosmol/kg (adjusted with D-mannitol). Isotonic
solution include the following (in mM): 85 NaCl, 2 MgCl2, 1.5
CaCl2, 10 glucose, 10 HEPES, pH 7.4, of osmolality
315 mosmol/kg (adjusted with D-mannitol). The hypotonic
solution with osmolality of 210 mosmol/kg was obtained by
omitting D-mannitol from the isotonic solution. For experi-
ments testing efficiency of an inhibitor, NaCl was replaced by
N-methyl-D-glucamine chloride (NMDG-Cl) after seal forma-
tion. All osmolalities were measured in a Wescor Vapro model
5520 osmometer (Wescor Inc., USA) calibrated by the manu-
facturer’s Optimol standard solutions.
SDS-PAGE and Western blotting
Protein was isolated from cells 36 h after transfection with
siRNA targeting ANO1, in a lysis buffer containing (in mM):
10 Tris–HCl, 10 EDTA, 1 % sodium dodecyl sulfate (SDS),
0.5% sodium deoxycholate, and 1% complete protease inhibitor
mixture (Roche, Denmark), pH 7.4, and was separated by 7 %
SDS-PAGE. Protein was subsequently transferred to nitrocellu-
lose membrane (Novex, Denmark). Membranes were
immunoblotted with monoclonal antibodies against ANO1
(SP31, ab64085) (Abcam, UK) or β-actin (Sigma-Aldrich,
Denmark), at 1:100 and 1:3,000 dilutions, respectively, overnight
at 4 °C in blocking buffer. Alkaline phosphatase-conjugated goat
anti-rabbit (ANO1) or goat anti-mouse (β-actin) secondary anti-
bodies (both Sigma-Aldrich, Denmark) were used at a 1:500
dilution in blocking buffer for 1 h at room temperature.
Membraneswerewashed extensively in Tris-buffered salinewith
Tween® 20 (TBST) and developed using BCIP/NBT solution
(Kirkegaard and Perry Laboratories, USA).
Cell proliferation and apoptosis assay
To assess cell proliferation and apoptosis, cells were plated in
duplicates on a 96-well plate and incubated in 100 μl of the
cell line appropriate media described above. Cells were
transfected with siRNA soon after complete attachment
(approx. 3 h after seeding). Cells were treated with
vehicle, 20 μM gemcitabine, 20 μM T16Ainh-A01, or
10 μM free NS3728 (see below) after culture in a
humidified 37 °C and 5 % CO2 incubator overnight.
BrdU incorpora t ion was measured using Cel l
Proliferation ELISA, BrdU (chemiluminescent) (Roche
Diagnostics A/S, Denmark) following the manufacturer’s
instructions. Caspases 3, 6, and 7 activation was evalu-
ated using Homogeneous Caspases Assay (fluorimetric)
(Roche Diagnostics A/S, Denmark).
Scratch wound healing assay
Cells were seeded into Essen ImageLock 96-well plates. Cells
were transfected with siRNA shortly after cells completely
attached at 80 % confluency. After 24 h of incubation, con-
fluent monolayers were scratched using the Essen 96-well
WoundMaker (Essen Bioscience, USA), washed two times
with the respective medium, and then incubated in medium
containing 5 μM aphidicolin (Sigma-Aldrich, Denmark) and
either T16Ainh-A01, CaCCinh-A01, or NS3728 or the appro-
priate control. The wound confluence was obtained and ana-
lyzed by using the IncuCyte phase-contrast imaging and
scratch wound assay system and software (Essen
Bioscience, USA).Wound closure was assessed by comparing
the mean relative wound density (%RWD) according to the
following formula: %RWD = 100×w(t)−w(0)/c(t)−w(t).
Here, w(t) is the density of wounded area at time t and c(t) is
the density of cell region at time t. Each experiment was
conducted in triplicates.
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Measurements of the free, intracellular calcium concentration,
[Ca2+]i
HPDE and BxPC-3 cells were incubated with 2 μM
Fura-2 AM (Sigma-Aldrich, Denmark) for 30 min at
37 °C. Cells were subsequently washed with Krebs
solution containing (in mM) 150 NaCl, 6 KCl, 1.5
CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES; pH was
adjusted to 7.4 using NaOH. Coverslips were mounted
on a recording chamber. In the beginning of the exper-
iment, cells were perfused with Krebs solution at 4 ml/
min until baseline was stable. Thereafter, the inhibitors
T16Ainh-A01, CaCCinh-A01 (20 μM), or NS3728
(10 μM) were infused and cells were stimulated with
general P2 receptor agonist ATP (10 μM). Changes in
[Ca2+]i were measured by a TIRF iMIC microscope
(TILL Photonics, Germany). Fura-2 AM loaded cells
were illuminated at 340 nm for 80 ms and 380 nm
for 80 ms at 1 s intervals using a TILL Polychrome
monochromator. Five hundred-nanometer emission im-
ages were captured by an image-intensifying, charge-
coupled device (CCD) camera (TILL Photonics,
Germany) and digitized by an image processing system
(TILL Photonics, Germany). The monochromator and
CCD camera were controlled by LA Live Acquisition
software, which was also used for image analysis. The
[Ca2+]i was presented as the Fura-2 ratio of the fluores-
cence signals obtained at 340/380 nm.
Materials and statistical analysis
2 - [ ( 5 - E t h y l - 1 , 6 - d i h y d r o - 4 - m e t h y l - 6 - o x o - 2 -
py r im i d i ny l ) t h i o ] -N - [ 4 - ( 4 -me t hoxypheny l ) - 2 -
t h i a z o l y l ] a c e t am i d e (T16A i n h -A01 ) , 6 - ( 1 , 1 -
dimethylethyl)-2-[(2-furanylcarbonyl)amino]-4,5,6,7-
tetrahydrobenzo[b]thiophene-3-carboxylic acid (CaCCinh-
A01), and aphidicolin were obtained from Sigma-
Aldrich at highest available purity. Stock solutions of
10 mM were prepared using dimethyl sulfoxide
(DMSO). The VRAC and CaCC inhibitor N-[3,5-
bis(trifluoromethyl)-phenyl]-N-[4-bromo-2-(1H-tetrazol-
5-yl)-phenyl] urea (NS3728) was a generous gift from
Palle Christophersen (NeuroSearch A/S, Denmark)
(stock solution 100 mM in DMSO). Earlier reports
found NS3728 to strongly bind to serum [17, 33]. We
therefore used NS3728 at 50 μM for physiological
assays such as proliferation, migration, and apoptosis
assays, all performed in media containing serum. It is
estimated that in these conditions the free inhibitor
concentration amounted to 10 μM.
The results of multiple experiments are presented
as means±s.e.m., and statistical analysis was carried
out by using one-way analysis of variance with
Tukey’s post test or Student’s t test, as appropriate.
P≤0.05 was considered statistically significant.
Results
ANO1 is functionally overexpressed in PDAC cells and is
the major mediator of CaCC current in these cells
To study the presence of ANO1 in PDAC cells, we evaluated the
expression of ANO1RNAbyRT-qPCR in several commercially
available cell lines (Mia PaCa-2, Panc-1, BxPC-3, and AsPC-1).
Mia PaCa-2, Panc-1, and BxPC-3were derived from the primary
tumor of an exocrine pancreatic cancer. AsPC-1 was established
from a local metastatic site in the ascites of a patient with PDAC
[42]. We used a normal pancreatic ductal epithelium derived cell
line (HPDE) as a control (Fig. 1). All cell lines showed an
increased mRNA level, ranging from 2.3±0.5- to 320±60-fold
over that in HPDE cells, in the Panc-1 and BxPC-3 cell lines,
respectively. Our earlier study compared ANO1mRNA levels in
Capan-1 PDAC cell line to Panc-1 and CFPAC-1 [45]; using
those data together with the values for HPDE and Panc-1 of the
present investigation, we calculated an ∼1,450-fold upregulation
of ANO1 in Capan-1 with respect to HPDE cells. Capan-1 is a
liver metastasis-derived cell line [42]. We selected the aggressive
pancreatic cancer cell lines AsPC-1 and BxPC-3 [6], as well as
Capan-1 and HPDE cells for further experiments. To validate
ANO1 expression also at the protein level in PDAC cells, we
usedWestern blot analysis (Fig. 1b). The results showed a similar
trend as observed for mRNA levels, with almost undetectable
ANO1 protein expression in HPDE cells and much higher levels
in the PDAC cell lines.
The functional expression of the protein in the plasma
membrane was assessed using the whole-cell patch-clamp
technique (Fig. 2). The time-dependent current activation
was recorded as described in “Materials and methods”.
Mean traces at Vm=+67 mV with 1 μM intracellular Ca
2+
revealed a large voltage-dependent current with activation at
positive membrane potentials in all cancer cell lines. This was
most pronounced in Capan-1 cells and barely detectable in
HPDE control cells (Fig. 2a). The instantaneous currents of
the three cancer cell lines followed GHK rectification
(Fig. 2b). It was thus possible to analyze steady-state
permeability’s using the GHK current equation (Fig. 2c).
The instantaneous current–voltage curve of a few cells re-
versed at far more positive potentials as the calculated equi-
librium potential for Cl−, those cells were omitted from the
calculation of permeability. Capan-1 and AsPC-1 cells
showed similar activation curves with half-maximal activation
of the channels (V1/2) at 61±8 and 58±8 mV, respectively.
This is in good agreement with earlier studies in ANO1-
transfected HEK293 cells [47]. BxPC-3 cells exhibited a
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significantly shifted permeability—voltage curve with V1/2=
30±8 mV. This altered gating in BxPC-3 cells may be due to
differential expression of other possible modulators (e.g.,
calmodulin) or mutations in the voltage- or Ca2+-sensing first
intracellular loop [47]. Further studies are needed to investi-
gate this phenomenon. Steady-state current–voltage curves
showed an outward-rectifying current with a reversal potential
(VRev) close to the Cl
− equilibrium potential (ECl, Fig. 2d).
Removal of Ca2+ from the pipette solution almost completely
eliminated this current in the cancer cell lines (Fig. 2d). These
biophysical properties match the characteristics described for
ANO1 [48].
To quantify the ANO1-mediated part of the total CaCC
current, we used siRNA knockdown, as well as the three Cl−
channel inhibitors NS3728 (10 μM), CaCCinh-A01 (20 μM),
and T16Ainh-A01 (20 μM). NS3728 is an inhibitor of VRAC
but was also found to inhibit CaCC [17]. CaCCinh-A01 is
known to potently inhibit CaCC current but was further shown
to alter [Ca2+]i signals [18]. T16Ainh-A01 is the latest devel-
oped inhibitor of ANO1; no unspecific effects have been
identified so far. Results are shown in Fig. 3. Application of
T16Ainh-A01 attenuated the CaCC current significantly in
both Capan-1 (43±8 % inhibition at +67 mV) and AsPC-1
(29±2 %) cells, but was ineffective on BxPC-3 cells (Fig. 3b).
CaCCinh-A01 inhibited the current more effectively in all
tested cell lines with 56±6 % inhibition in Capan-1, 46±
6 % in AsPC-1, and 29±3 % in BxPC-3 cells, respectively
(all calculated at +67 mV). Application of NS3728 resulted in
the most pronounced inhibition in all cell lines with 77±26 %
in Capan-1, 67±9 % in AsPC-1, and 54±8 % in BxPC-3 cells
at +67 mV. Using siRNA targeting ANO1, the CaCC currents
decreased by 88±42 % in Capan-1, 89±51 % in AsPC-1, and
84±23 % in BxPC-3 cells when compared to currents mea-
sured in cells transfected with scrambled siRNA (MOCK)
(Fig. 3c). Successful knockdown of ANO1 protein expression
was confirmed using Western blot (Fig. 3d). Protein expres-
sion was decreased to 37±8 % in Capan-1, 54±14 % in
AsPC-1, and 20±7 % in BxPC-3 cells.
All tested cells exhibit a large volume-regulated anion current
The above results provide compelling evidence that ANO1
carries the major fraction of CaCC in PDAC cells. In order to
further characterize the role of Cl− channels in PDAC cells, we
next evaluated the role of the volume-regulated anion channel
(VRAC or LRRC8), the genetic identity of which was recently
identified [34, 44]. We studied VRAC phenotype by whole-cell
voltage-clamp recordings of cells exposed to a hypotonic bath
solution and results are shown in Fig. 4. To rule out contributions
from CaCC, Ca2+ was omitted from the pipette solution and
10mMEGTAwas included. A bath solution change from 315 to
210mosmol/kg (removal of D-mannitol) caused the cells to swell
and evoked a large current that was completely inhibited upon
application of 10μMofNS3728 (Fig. 4a). Both the activation by
volume expansion and the NS3728-mediated inhibition were
reversible. The time course of swelling activation varied signif-
icantly among individual cells. However, large VRAC currents
were detected in all tested cell lines withmost prominent currents
seen in Capan-1 and BxPC-3 cells (Fig. 4b). We also observed
VRAC current inactivation at Vm>0 mVwith flat tail currents at
depolarized membrane potentials, as also reported previously
[30]. This voltage dependency of IVRAC was pronounced in
Fig. 1 ANO1 is upregulated at themRNA and protein levels in all PDAC
cell lines tested. a Mean ANO1 expressions measured by RT-qPCR in
five PDAC cell lines (Panc-1, Mia PaCa-2, BxPC-3, AsPC-1, and Capan-
1) compared to the immortalized human pancreatic ductal cell line
(HPDE). Data for Capan-1 was taken from [45] and recalculated relative
to the value in the HPDE cell line. b Western blot analysis in three
pancreatic cancer cell lines and HPDE with β-actin as a loading control.
Mean±s.e.m. of n=4–5 individual experiments
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HPDE and Capan-1 cells; BxPC-3 and AsPC-1 cells showed
weaker inactivation at positive voltages (Fig. 4b, c). It was
recently suggested that VRAC is a heteromer formed by different
subtypes of the LRRC8 protein family, which exhibit different
gating at positive potential [44]. The apparent difference in gating
between the cell lines might be due to differential expression of
the different LRRC8 subtypes. However, further studies are
required to confirm this. The VRev of the activated current was
−25.7±0.7 mV (HPDE), −24±2 mV (Capan-1), −24±2 mV
(AsPC-1), and 28±3 mV (BxPC-3), as compared to the calcu-
lated Cl− equilibrium potential of −20 mV (Fig. 4c).
T16Ainh-A01 and CaCCinh-A01 do not inhibit VRAC;
NS3728 is a potent inhibitor of both VRAC and ANO1
In order to evaluate the inhibitors of the two Cl− channels, we
studied effects of the ANO1 inhibitors, T16Ainh-A01 and
CaCCinh-A01, and of the VRAC inhibitor, NS3728, on
volume-induced currents. Cells were exposed to hypotonic solu-
tion in the absence of intracellular Ca2+, and after full activation
of the membrane current, the HPDE and BxPC-3 cells were
exposed to 20 μM T16Ainh-A01 or CaCCinh-A01 followed by
NS3728 (Fig. 5a, b). Statistical analyses of currents were per-
formed at Vm=+65 mV before and after application of the
respective inhibitor (Fig. 5c). Neither T16Ainh-A01 nor
CaCCinh-A01 inhibited the VRAC currents significantly. In
Fig. 2 PDAC cells exhibit large Ca2+- and voltage-activated Cl− currents
that were not detected in HPDE control cells. Whole-cell patch-clamp
recordings in HPDE, Capan-1, AsPC-1, and BxPC-3 cells. Vout=0 mV
and a pulse sequence from −100 to +100 mVof 20 mV increments was
applied as described in “Materials and methods.” a Mean currents at +
67 mV. Statistical analysis was made at the end of the voltage step. b
Representative instantaneous current–voltage relationships of the differ-
ent cancer cell lines fitted to the GHK current equation. c Normalized
steady-state permeability calculated using the GHK current equation and
fitted to the Boltzmann distribution. V1/2 is the voltage for half-maximal
activation of the channels. d Steady-state I–V relationships of Capan-1,
AsPC-1, and BxPC-3 cells in the presence and absence of intracellular
Ca2+. (n)=number of cells measured; asterisk, significant when compared
to HPDE (ANOVA); number sign, significantly different from AsPC-1
cells; single asterisk and single number sign=p≤0.05; double asterisk
and double number sign=p≤0.01; triple asterisk and triple number sign=
p≤0.001
Fig. 3 ANO1 is the major contributor of CaCC currents in PDAC cells
and is sensitive to Cl− channel inhibitors and siRNA. Whole-cell patch-
clamp recordings with 1 μM Ca2+ in pipette solution. a Representative
current traces measured in Capan-1 cells upon exposure to different
inhibitors. b Quantification of CaCC currents at +67 mV recorded with
inhibitors compared to currents in presence of DMSO; currents of
siANO1 cells were compared to those of MOCK transfected cells. c
Steady-state I–V relationships of cells transfected with either scrambled
siRNA (MOCK) or siRNA targeting ANO1. d Densitometric quantifica-
tion of Western blot analysis of siRNA knockdown. β-Actin was used as
a loading control. (n)=number of individual experiments
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contrast, NS3728 decreased the fully activated VRAC current to
17±4 % of that in the absence of the inhibitor. NS3728 was
originally found to inhibit VRAC [12], but it also inhibited CaCC
(Fig. 3) as also shown in another study [17]. To elucidate a
possible effect of NS3728 on ANO1, we used HEK293 cells
transiently transfected with mANO1-GFP as described recently
[10]. Transfection with ANO1-GFP resulted in induction of a
Ca2+- and voltage-dependent, outwardly rectifying current
(Fig. 6a) with a Vrev near ECl (Fig. 6b). These currents were
almost completely inhibited when treated with NS3728 (10 μM
free concentration). The associated IC50 calculated at Vm=+
48 mV was estimated to be 1.3 μM (Fig. 6c).
ANO1 plays no role in PDAC cell proliferation; VRAC does
To assess the roles of ANO1 and VRAC in cell proliferation,
we measured BrdU incorporation in mock (5 nM) and ANO1
siRNA (50 nM) transfected cells, as well as in the presence or
absence of T16Ainh-A01 (20 μM), CaCCinh-A01 (20 μM),
NS3728 (10 μM free concentration), and the standard
chemotherapeutical drug gemcitabine (20 μM, not shown)
(Fig. 7). siRNA transfection targeting ANO1 did not cause
any significant change in proliferation in any of the tested cell
lines (Fig. 7a). This result indicates, quite unexpectedly, that
ANO1 plays no major role in cell cycle progression. In agree-
ment with this, none of the ANO1-overexpressing cancer cells
showed any significant decrease in proliferation in response to
T16Ainh-A01 (Fig. 7b). A slight, but non-significant decrease
of proliferation was seen in BxPC-3 cells after T16Ainh-A01
treatment, although T16Ainh-A01 did not affect CaCC cur-
rents in these cells in patch-clamp recordings. Also HPDE
cells, which do not exhibit great CaCC (Fig. 2a), showed
inhibited proliferation with T16Ainh-A01. The more potent
inhibitor CaCCinh-A01 decreased proliferation in Capan-1
slightly and had larger effect on BxPC-3 cells. Capan-1 cells
that reacted most prominently to CaCCinh-A01 (56±6 %
Fig. 4 All tested cell lines exhibit large swelling-activated Cl− currents.
Response of whole-cell currents to hypotonic bath solution; pipette
solution was 0 μM Ca2+ with 10 mM EGTA. a Time course of currents
in Capan-1 cells as described in “Materials andmethods.”Currents at −47
and +93mVwere corrected for liquid junction potential, n=24 cells. Rate
of activation varied among cells. b Currents at +65 mV, measured using
the voltage protocol described in legend of Fig. 2. c Steady-state I–V
relationships given as mean±s.e.m. (n)=number of cells
Fig. 5 T16Ainh-A01 and CaCCinh-A01 do not inhibit VRAC. a, b
Representative current densities over time in HPDE and BxPC-3 cells,
respectively, exposed to hypotonic bath solution and pipette solution
containing 0 μM Ca2+. Inhibitors were applied for 3–10 min when the
maximum volume-activated current was obtained. cQuantification of the
effect shown in percent of maximum VRAC current at +65 mV. Data
shown are mean±s.e.m.
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inhibition) in patch-clamp measurements showed only a slight
decrease in proliferation after addition of the inhibitor.
Most importantly, Fig. 7b also shows that application of
NS3728 resulted in a pronounced decrease in cellular prolifer-
ation in all cells. The most drastic effect was observed in HPDE
control cells. The very low expression level of ANO1 in this
cell line suggests that the inhibition of proliferation by NS3728
is not ANO1-mediated, but rather reflects inhibition of VRAC
or altered [Ca2+]i signaling (Fig. 8). In agreement with this, it is
long known that VRAC is involved in progression throughout
the cell cycle of different cancer types [17, 40]. As expected,
gemcitabine treatment caused an almost complete inhibition of
proliferation in all tested cells (data not shown).
All Cl− channel inhibitors alter intracellular Ca2+ signals
Activation of CaCC requires an increase in [Ca2+]i, which can
be achieved by stimulation of receptors such as purinergic
Fig. 6 NS3728 inhibits ANO1.
Whole-cell currents of HEK293
cells transiently transfected with
mANO1-GFP with 1 μM free
Ca2+ in pipette solution. a
Currents recorded using the step
protocol with and without
NS3728 (10 μM) b I–V
relationships. Cl− equilibrium
potential, ECl=−28.5 mV. c
Dose–response curve of
NS3728 at Vm=+48 mV. The
solid line is the fit by the Hill
equation (n=3–8 cells, depending
on concentration)
Fig. 7 VRAC, but not ANO1,
regulates cellular proliferation. a
Summary of BrdU incorporation
in HPDE, Capan-1, AsPC-1, and
BxPC-3 cells after various
treatments as indicated. Cells
were transfected shortly after
complete attachment (approx. 3 h)
and BrdU incorporation was
assessed 36 h after transfection.
To investigate effect of inhibitors,
cells were incubated for 24 h with
respective inhibitor. Values
shown are relative to appropriate
control. Data shown represents
mean±s.e.m. of n=4–6 individual
experiments. **p≤0.01 and
***p≤0.001 when compared
with control
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receptors. Therefore, we studied the effect of Cl− channel
inhibitors on changes in [Ca2+]i induced by purinergic signal-
ing. We chose HPDE cells with very low expression levels of
ANO1 and the highly ANO1 overexpressing cell line BxPC-3
for investigation. Fura-2 loadedHPDE and BxPC-3 cells were
stimulated with ATP (10 μM) (Fig. 8) or exposed to the
inhibitor prior to stimulation. ATP stimulation caused a 0.46
±0.03 peak increase in the Fura-2 ratio in HPDE and 0.55±
0.02 in BxPC-3 cells. Cells first exposed to T16Ainh-
A01 showed a significantly attenuated peak response to
ATP resulting in a 0.32±0.03 (HPDE) and 0.42±0.03
(BxPC-3) change in Fura-2 ratio (Fig. 8). However, no
effect of the inhibitor on basal Ca2+ level was observed.
Exposure to CaCCinh-A01 (20 μM) caused a reversible
increase in [Ca2+]i in both cell lines tested. Subsequent
application of ATP elicited no additional effect on top
of inhibitor-induced [Ca2+]i increase. No significant
change in basal [Ca2+]i was observed in HPDE and
BxPC-3 cells when exposed to NS3728 (10 μM).
Pretreatment with NS3728 caused a significantly atten-
uated response in HPDE cells (0.21±0.01 Δratio 340/
380 nm). In contrast, in BxPC-3 cells, NS3728 pretreat-
ment elicited a prolonged increase in [Ca2+]i upon ATP
stimulation. The responses are summarized in Fig. 8b.
A
B
HPDE
BxPC-3
Fig. 8 Cl− channel inhibitors alter ATP-induced Ca2+ signals. Intracel-
lular Ca2+ measurements in FURA-2 loaded HPDE and BxPC-3 cells. a
Representative single-cell traces of individual experiments. Different
substances were applied as indicated. ATP was applied at 10 μM,
T16Ainh-A01 and CaCCinh-A01 at 20 μM, and NS3728 at 10 μM. b
Summary of maximum ATP-induced changes in [Ca2+]i; for CaCCinh-
A01, these values may be overestimates as the peak response was not
present. (n)=number of individual experiments; each containing between
5–45 single cells.***p≤0.001 when compared to no inhibitor condition;
##p≤0.01 when compared with HPDE no inhibitor
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ANO1 is crucial for cell migration
Earlier studies already revealed ANO1 as a crucial player in
cell migration [15, 35]. We therefore assessed a possible
contribution of ANO1 in PDAC cell migration using wound
healing assay. Capan-1 cells did not show any wound closure
in this time frame and were therefore not investigated. The
experiments were conducted in the presence of 5 μM
aphidicolin to rule out a possible effect on cell proliferation.
Figure 9a shows relative wound density (see Materials and
Methods) over time, monitored in AsPC-1 cells transfected
with either scrambled siRNA (5 nM)(MOCK) or siRNA
targeting ANO1 (50 nM). ANO1 knockdown cells showed a
significantly decreased migration (Fig. 9a). However, the
relative wound density curve over time saturated after 36 h
and only partial wound closure (24±4 %) was reached
in the control situation. AsPC-1 cells were therefore not
well suited for studies of lateral motility. BxPC-3 cells
showed a much more rapid wound closure with com-
plete closure after 60 h in most of the control experi-
ments. Migration was significantly decreased to 30±8 %
after 60 h after transfection with siANO1 (Fig. 9b). In
another series of experiments, we exposed the cells to
T16Ainh-A01 (20 μM), CaCCinh-A01 (20 μM), and
NS3728 (10 μM free concentration) (Fig. 9c).
Application of T16Ainh-A01 had no detectable effect
on migratory behavior. CaCCinh-A01 seemed to slow
down wound closure; however, this did not reach sig-
nificance. When exposed to NS3728, an initial acceler-
ation was observed that began to saturate after 30 h and
resulted in 54±8 % relative wound density after 60 h.
All inhibitors were applied at several orders of magni-
tude above the IC50 value for ANO1, yet none caused
effects on wound closure comparable to those observed
in the knockdown cells. These results are in good
agreement with whole-cell patch-clamp recordings of
CaCC currents, in which ANO1 knockdown also
showed the strongest inhibitory effect (Fig. 3).
Discussion
In the present study, we provided compelling evidence that
ANO1 is functionally overexpressed in human pancreatic
cancer cell lines and that it carries the major component of
CaCC currents in these cells. Below, we discuss the possible
roles of ANO1 in PDAC cell behavior, as well as some
unexpected effects of putative ANO1 inhibitors.
All Cl− channel inhibitors inhibit CaCC but also have other
side effects
siRNA knockdown of ANO1 almost completely abolished the
CaCC-mediated current in all cells tested. Surprisingly, to
date, the most specific inhibitor of ANO1, T16Ainh-A01
[24], did not inhibit the CaCC current in BxPC-3 cells, even
when applied several orders of magnitude above the IC50
value for ANO1 (20 μM) [24]. Inhibition was observed in
other PDAC cells, but efficacy was still only moderate
(Capan-1 and AsPC-1 cells) (Fig. 3). A recent study by
Scudieri et al. of ANO1 in bronchial epithelial cells reports
similar observations [39]. They found that siRNA targeting
ANO1 diminished Ca2+-activated Cl− secretion almost entire-
ly, yet T16Ainh-A01 (10 μM) showed relatively weak inhibi-
tion. Moreover, these researchers found that cells prior ex-
posed to T16Ainh-A01 (10 μM) had significantly attenuated
UTP-induced Cl− secretion in short-circuit currents record-
ings. This is in line with our measurements of attenuated ATP-
induced increase in [Ca2+]i in the presence of this inhibitor
Fig. 9 ANO1 supports migration of PDAC cells. Wound healing assay is
shown as relative wound density (density of wounded area relative to
confluency of cell region) over time. Aphidicolin (5 μM) was added to
stop proliferation. a AsPC-1 cells and b BxPC-3 cells after transfection
with either scrambled siRNA (5 nM) or siRNA targeting ANO1 (50 nM).
c BxPC-3 cells in presence of different inhibitors. Data shown represents
mean±s.e.m. of n=4 experiments; each run was carried out in triplicates
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(Fig. 8). We also observed off-target effects of T16Ainh-A01
when applied in proliferation experiments. The inhibitor re-
sulted in a significant inhibition of proliferation in HPDE
cells, which almost completely lack ANO1 (Figs. 1, 2, and
7) and yet have attenuated response to ATP-induced [Ca2+]i
signals. Taken together, these results suggest that T16Ainh-
A01 is not suited as a specific inhibitor of ANO1 and that its
mechanism of action might either be more indirect or may
depend on the type of cell, ANO1 isoforms and/or experimen-
tal conditions.
CaCCinh-A01 inhibited CaCC current stronger in all cell
lines tested (Fig. 3). No effect of CaCCinh-A01 on VRAC was
observed (Fig. 5b). However, we revealed large unspecific
effects of the inhibitor on [Ca2+]i which slowly increased with
the inhibitor, ATP stimulation had no further effects, and the
effects were fully reversible (Fig. 8). Similar unspecific effects
of the inhibitor were also observed by others [18]. CaCCinh-
A01 was further reported to inhibit other CaCCs [18].
The third inhibitor used in this investigation, NS3728, also
has limited specificity. It is an inhibitor of VRAC and ANO1
(Figs. 4 and 6), but may also inhibit other molecular entities
involved in CaCC [17]. We further found that NS3728 altered
ATP-induced [Ca2+]i signals in a cell line-dependent fashion
(Fig. 8), such that PDAC cells were even more responsive to
ATP. Our study thus illustrates that presently available inhibitors
are problematic and more selective inhibitors are still required.
ANO1 has no role in cell proliferation but supports migration
The physiological role of CaCC (e.g., ANO1) in pancreatic
ducts is in mediating secretion [25, 45]. One of the interesting
questions is how overexpression of this channel could regulate
other cellular functions in PDAC. We found no correlation
between ANO1 protein level and cell proliferation (Figs. 1
and 7) or effector caspase activation after gemcitabine treat-
ment (online resources Fig. S1) in any of the tested cells. Our
findings are in agreement with recent reports on head and neck
squamous cell carcinoma cells, where no correlation between
ANO1 expression and channels function (siRNA knockdown
or CaCCinh-A01) and cell proliferation was found [1, 35].
However, these results stand in contrast to reports in which
ANO1 was shown to play a pro-proliferative role in cancer
cells. These studies use different approaches covering xeno-
graft models [7], RNAi knockdown [22], as well as small-
molecule inhibitors [23]. The latter study was entirely based
on T16Ainh-A01 and uses the pancreatic cancer cell line
CFPAC-1, which has also a defect in another Cl− channels
(i.e., CFTR). Unspecific effects of the inhibitor as shown in
the present investigation may explain these results. However,
the function of ANO1 in cell proliferation may depend on cell
environment, cell type, or other factors. The most significant
decrease in proliferation of PDAC cell lines was observed
with NS3728 exposure, an effect which can probably be
assigned to inhibition of VRAC and cell volume regulation.
In addition, altered [Ca2+]i signaling, as shown in Fig. 8, may
also contribute to NS3728-mediated inhibition of cell prolif-
eration. Taken together, no correlation between ANO1 expres-
sion and PDAC cell proliferation was observed in the present
study. However, our results once again highlight the impor-
tance of VRAC in proliferation previously shown in several
cell types [13].
Most importantly, we found that siRNA knockdown of
ANO1 resulted in a significantly decreased migratory rate in
both AsPC-1 and BxPC-3 cells (Fig. 9). This pro-migratory
role of ANO1 was further confirmed by pharmacological
inhibition of the channel. Thus, CaCCinh-A01 and NS3728
caused a decrease in migration in BxPC-3 cells, whereas
T16Ainh-A01 was found to be ineffective. These results cor-
relate directly with the inhibitory potential of these inhibitors
on CaCC current (Fig. 3b), suggesting that ANO1 functions as
an ion channel which has a crucial role in supporting migra-
tion. These results fit with the commonly accepted model for
cell migration, where cell shape changes caused by local
volume changes are driven by fluxes of K+ and Cl− ions and
accompanied by H2O [38]. We and others provided compel-
ling evidence that ANO1 is involved in the migratory machin-
ery in other cell types [15, 35]. On the other hand, Capan-1
cells, which showed the highest functional ANO1 expression
in the present study, migrate very slowly, whereas HPDE cells
which are almost devoid of ANO1 showed fast wound closure
in a scratch assay (data not shown). This indicates that where-
as Cl− currents are likely a prerequisite to cell migration, the
current need not be carried by ANO1. In HPDE cells, VRAC
may be a possible candidate.
Our study points out that to further target the functions of
ANO1 and VRAC in cancers overexpressing these currents,
development of more selective small-molecule inhibitors
would be useful. In conclusion, our study shows that ANO1
is functionally overexpressed in PDAC cells and its role is
related to cell migration but not to proliferation. ANO1 may
therefore pose a good target for control of metastatic potential
of PDAC.
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